window.lintrk('track', { conversion_id: 15481201 });

DrugCoat

DRUGCOAT

Excellence in Pharma Polymer

US-DMF available

DRUGCOAT polymer range of products has excellent potential as versatile & unique in different applications in NDDS including customized and newer applications. Therefore, the pharma industry has now started looking for newer coating materials and is in a process of shifting from conventional coating materials to NEXTGEN polymer i.e. Methacrylic acid copolymers.

Types/Series

The best range of methacrylate co-polymer for enteric coating, protective coating, taste masking, and sustained release formulations are offered by Vikram Thermo (India) Limited under the brand name DRUGCOAT®.

DRUGCOAT L & S Series ENTERIC COATING FORMULATION
  • DRUGCOAT L 30D
  • DRUGCOAT L 100-55
  • DRUGCOAT L 100-55D
  • DRUGCOAT L 100
  • DRUGCOAT L 12.5
  • DRUGCOAT S 100
  • DRUGCOAT S 12.5
  • DRUGCOAT FS 30D

DRUGCOAT E Series TASTE MASKING AND PROTECTIVE COATING
  • DRUGCOAT E 100
  • DRUGCOAT E PO
  • DRUGCOAT E 12.5

DRUGCOAT RL/RS & NE Series SUSTAINED RELEASE FORMULATION
  • DRUGCOAT RL 100
  • DRUGCOAT RL PO
  • DRUGCOAT RL 12.5
  • DRUGCOAT RS 100
  • DRUGCOAT RS PO
  • DRUGCOAT RS 12.5
  • DRUGCOAT NE 30D

DRUGCOAT L & S Series ENTERIC COATING FORMULATION

DRUGCOAT SERIES MONOGRAPHS PHYSICAL FORM DISSOLUTION PROPERTIES
AQUEOUS ENTERIC COATING
DRUGCOAT L30D USP/NF: Methacrylic Acid And Ethyl Acrylate Copolymer Dispersion
Ph. Eur.: Methacrylic Acid-Ethyl Acrylate Copolymer(1:1) Dispersion 30%		 Aqueous Dispersion 30% Dissolve above pH 5.5
DRUGCOAT L 100-55 USP/NF: Methacrylic Acid And Ethyl Acrylate Copolymer
Ph. Eur.: Methacrylic Acid- Ethyl Acrylate Copolymer (1:1) Type A		 Powder
DRUGCOAT L 100-55D USP/NF: Partially–Neutralized Methacrylic Acid & Ethyl Acrylate Copolymer
Ph. Eur.: Methacrylic Acid- Ethyl Acrylate Copolymer (1:1) Type B		 Powder
NON AQUEOUS ENTERIC COATING
DRUGCOAT L 100 USP/NF: Methacrylic Acid And Methyl Methacrylate Copolymer (1:1)
Ph. Eur.: Methacrylic Acid – Methyl Methacrylate Copolymer (1:1)		 Powder Dissolve above pH 6.0
DRUGCOAT L 12.5 Organic Solution 12.5%
COLON TARGETED ENTERIC COATING
DRUGCOAT S 100 USP/NF: Methacrylic Acid And Methyl Methacrylate Copolymer (1:2)
Ph. Eur.: Methacrylic Acid – Methyl Methacrylate Copolymer (1:2)		 Powder Dissolve above pH 7.0
DRUGCOAT S 12.5 Organic Solution 12.5%
DRUGCOAT FS 30D Aqueous Dispersion 30% Dissolve above pH 7.0

DRUGCOAT E Series TASTE MASKING AND PROTECTIVE COATING

DRUGCOAT SERIES MONOGRAPHS PHYSICAL FORM DISSOLUTION PROPERTIES
DRUGCOAT E 100 USP/NF: Amino Methacrylate Copolymer
Ph. Eur.: Basic Butylated Methacrylate Copolymer		 Granules Dissolve up to pH 5.0
Soluble in Gastric Fluid
DRUGCOAT E PO Powder
DRUGCOAT E 12.5 Organic Solution 12.5%

DRUGCOAT RL/RS & NE Series SUSTAINED RELEASE FORMULATION

DRUGCOAT SERIES MONOGRAPHS PHYSICAL FORM DISSOLUTION PROPERTIES
DRUGCOAT RL 100 USP/NF: Ammonio Methacrylate Copolymer, Type A
Ph. Eur.: Ammonio Methacrylate Copolymer, Type A		 Granules pH-independent swelling
DRUGCOAT RL PO Powder
DRUGCOAT RL 12.5 Organic Solution 12.5%
DRUGCOAT RS 100 USP/NF: Ammonio Methacrylate Copolymer, Type B
Ph. Eur.: Ammonio Methacrylate Copolymer, Type B		 Granules
DRUGCOAT RS PO Powder
DRUGCOAT RS 12.5 Organic Solution 12.5%
DRUGCOAT NE 30D USP/NF: Ethyl Acrylate And Methyl Methacrylate Copolymer Dispersion
Ph. Eur.: Polyacrylate Dispersion 30%		 Aqueous Dispersion 30%

By Application

DRUGCOAT L & S Series

  • pH-Dependent drug release
  • Protection of API from gastric fluid
  • Protection of gastric mucosa from API
  • Increase storage stability
  • GI and colon targeting
  • Insulate hygroscopic cores
  • Maintain the better stability of phthalate group coating agent
  • Enteric coating of API formulations

DRUGCOAT E Series

  • pH Dependent Drug release
  • Protection of API from environmental factors
  • Improves patient compliance
  • Lowest WVTR in its Class
  • Moisture Protection
  • Higher stability
  • Taste and Odor Masking
  • Improve storage stability of Sensitive API’s

DRUGCOAT RL/RS & NE Series

  • For Sustain Release of API’s.
  • Customized release profiles
  • Prolongation of effective plasma level
  • Reduction of total dose
  • Reduce risk of dose dumping
  • Reduce toxicological effects of API’s
  • Reduction of Administration frequency
  • Increase patient compliance

Let’s explore opportunities

Our company revolves around giving maximum to the two pillars that lay the foundation for our business: People and Product. Through constant R&D and innovation, the company plans to build a better future without compromising the quality and safety to reach a higher level of excellence in healthcare facilities.

Let’s create opportunities together
hand-shake-1(1)